A detailed history of Marshall Wace, LLP transactions in Incyte Corp stock. As of the latest transaction made, Marshall Wace, LLP holds 1,278,310 shares of INCY stock, worth $90.8 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
1,278,310
Previous 33,542 3711.07%
Holding current value
$90.8 Million
Previous $2.03 Million 4056.22%
% of portfolio
0.11%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$57.33 - $68.61 $71.4 Million - $85.4 Million
1,244,768 Added 3711.07%
1,278,310 $84.5 Million
Q2 2024

Aug 14, 2024

SELL
$51.18 - $63.75 $13.2 Million - $16.5 Million
-258,159 Reduced 88.5%
33,542 $2.03 Million
Q1 2024

May 15, 2024

BUY
$56.55 - $66.59 $14.1 Million - $16.6 Million
249,042 Added 583.8%
291,701 $16.6 Million
Q4 2023

Feb 14, 2024

SELL
$52.16 - $64.19 $28.5 Million - $35.1 Million
-546,865 Reduced 92.76%
42,659 $2.68 Million
Q3 2023

Nov 14, 2023

BUY
$57.77 - $65.93 $25.7 Million - $29.3 Million
444,439 Added 306.33%
589,524 $34.1 Million
Q2 2023

Aug 14, 2023

SELL
$60.95 - $75.51 $2.32 Million - $2.87 Million
-38,005 Reduced 20.76%
145,085 $9.03 Million
Q1 2023

May 15, 2023

SELL
$70.23 - $86.01 $5.88 Million - $7.2 Million
-83,722 Reduced 31.38%
183,090 $13.2 Million
Q4 2022

Feb 14, 2023

BUY
$67.18 - $84.11 $14.7 Million - $18.4 Million
219,012 Added 458.18%
266,812 $21.4 Million
Q3 2022

Nov 14, 2022

BUY
$66.18 - $82.86 $3.16 Million - $3.96 Million
47,800 New
47,800 $3.19 Million
Q1 2022

May 16, 2022

SELL
$66.02 - $79.71 $27 Million - $32.6 Million
-408,989 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$63.34 - $74.11 $23.1 Million - $27.1 Million
365,425 Added 838.82%
408,989 $30 Million
Q3 2021

Nov 15, 2021

BUY
$68.67 - $84.02 $2.12 Million - $2.59 Million
30,850 Added 242.65%
43,564 $3 Million
Q2 2021

Aug 13, 2021

SELL
$79.87 - $87.53 $6.58 Million - $7.22 Million
-82,440 Reduced 86.64%
12,714 $1.07 Million
Q1 2021

May 17, 2021

BUY
$76.02 - $100.5 $7.23 Million - $9.56 Million
95,154 New
95,154 $7.73 Million
Q2 2020

Aug 13, 2020

SELL
$74.18 - $108.93 $4,821 - $7,080
-65 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$63.18 - $85.97 $2.03 Million - $2.77 Million
-32,176 Reduced 99.8%
65 $5,000
Q4 2019

Feb 14, 2020

SELL
$73.04 - $95.72 $4.49 Million - $5.88 Million
-61,470 Reduced 65.6%
32,241 $2.82 Million
Q3 2019

Nov 14, 2019

BUY
$72.82 - $86.52 $4.82 Million - $5.72 Million
66,132 Added 239.79%
93,711 $6.96 Million
Q2 2019

Aug 14, 2019

BUY
$73.52 - $88.7 $831,952 - $1 Million
11,316 Added 69.58%
27,579 $2.34 Million
Q1 2019

May 14, 2019

BUY
$63.56 - $88.17 $1.03 Million - $1.43 Million
16,263 New
16,263 $1.4 Million
Q4 2018

Feb 14, 2019

SELL
$58.5 - $69.94 $2.12 Million - $2.53 Million
-36,209 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$61.75 - $74.23 $2.24 Million - $2.69 Million
36,209 New
36,209 $2.5 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.8B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.